<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Jw Cayman Therapeutics Co Ltd — News on 6ix</title>
    <link>https://6ix.com/company/jw-cayman-therapeutics-co-ltd</link>
    <description>Latest news and press releases for Jw Cayman Therapeutics Co Ltd on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Fri, 31 Oct 2025 09:38:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/jw-cayman-therapeutics-co-ltd" rel="self" type="application/rss+xml" />
    <item>
      <title>JW Therapeutics and Regeneron Expand Strategic Collaboration Agreement to Advance TCR-T Cell Therapy Development and Maximize Global Platform Potential</title>
      <link>https://6ix.com/company/jw-cayman-therapeutics-co-ltd/news/jw-therapeutics-and-regeneron-expand-strategic-collaboration-agreement-to-advance-tcr-t-cell-therapy-development-and-maximize-global-platform-potential</link>
      <guid isPermaLink="true">https://6ix.com/company/jw-cayman-therapeutics-co-ltd/news/jw-therapeutics-and-regeneron-expand-strategic-collaboration-agreement-to-advance-tcr-t-cell-therapy-development-and-maximize-global-platform-potential</guid>
      <pubDate>Fri, 31 Oct 2025 09:38:00 GMT</pubDate>
      <description>JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced the execution of an Amendment to its strategic collaboration agreement with Regeneron Pharmaceuticals, Inc. (&quot;Regeneron&quot;), a leading global biotechnology company. This amendment not only signifies a major upgrade in long-term partnership between the two companies, but also marks the beginning of a new phase of collabora</description>
    </item>
    <item>
      <title>JW Therapeutics Announces Approval of Relmacabtagene Autoleucel Injection (Carteyva®) for Marketing in Macao</title>
      <link>https://6ix.com/company/jw-cayman-therapeutics-co-ltd/news/jw-therapeutics-announces-approval-of-relmacabtagene-autoleucel-injection-carteyvar-for-marketing-in-macao</link>
      <guid isPermaLink="true">https://6ix.com/company/jw-cayman-therapeutics-co-ltd/news/jw-therapeutics-announces-approval-of-relmacabtagene-autoleucel-injection-carteyvar-for-marketing-in-macao</guid>
      <pubDate>Thu, 05 Jun 2025 01:04:00 GMT</pubDate>
      <description>JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that its new drugapplication (NDA) for the CAR-T cell immunotherapy product Carteyva® (relma-cel, targeting CD19) was approved by the Macao Special Administrative Region Government&apos;s Drug Regulatory Authority. This marks the first overseas market access for the product after its approval in mainland China, as well as a</description>
    </item>
  </channel>
</rss>